Compare Novartis AG (NVS) vs TE Connectivity plc Ordinary Shares (TEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs TE Connectivity plc Ordinary Shares — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while TE Connectivity plc Ordinary Shares trades at $217.7 (market cap $62.05B). The key difference: Novartis AG is far larger — about 4.3× TE Connectivity plc Ordinary Shares's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| NVS | TEL | |
|---|---|---|
Market Cap | $268.57B | $62.05B |
Volume | 1,532,573 | 1,425,198 |
Sector | Health | Technology |
52-Week High | $168.62 | $249.00 |
52-Week Low | $121.80 | $195.84 |
Typical Hold Time | 82 Days | — |
Enterprise Value | $309.89B | $66.44B |
Dividend Yield | 3.31% | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About TE Connectivity plc Ordinary Shares
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →
